Leading experts discuss the evolving role of immunotherapy and neoadjuvant therapies in cSCC and BCC treatment.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Patel explained that while most basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs) are treated surgically, a subset of patients with recurrent, advanced or metastatic disease require systemic therapy. He noted systemic treatment is also considered for some patients with a high disease burden for whom surgery would be excessively disfiguring or challenging. Luke highlighted the increasing use of immunotherapy in the neoadjuvant setting across cancer types to facilitate organ preservation and improve outcomes. Hamid discussed a neoadjuvant trial in cSCC that demonstrated high pathologic complete response rates and helped make previously unresectable tumors suitable for surgery. The discussants agreed that the impressive responses observed with neoadjuvant cemiplimab set the stage for testing shortened treatment courses and even nonsurgical management in some cSCC patients.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More